Intelligence · Clinical pipeline
Oncology · Phase III
Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- AstraZeneca 75 programs
- Chinese Academy of 70 programs
- HOFFMANN-LA ROCHE 68 programs
- MSD Merck Sharp 56 programs
- First People's Hospital 53 programs
- Ningbo Cancer Hospital 44 programs
- United Therapeutics Europe 43 programs
- Anaxis Pharma 37 programs
- AstraZeneca 37 programs
- Novartis India 32 programs
- George Institute for 29 programs
- Takeda 28 programs
Pipeline programs
-
D702AC00001
AstraZeneca AB
HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
1 trial -
D702BC00001
AstraZeneca AB
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
1 trial -
D702FC00001
AstraZeneca AB
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
1 trial -
D702GC00001
AstraZeneca AB
Lung Cancer
1 trial -
D702NC00001
AstraZeneca AB
Biliary Tract Cancer
1 trial -
D7310C00001
AstraZeneca AB
Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
1 trial -
D7402C00001
AstraZeneca AB
Large B-cell Lymphoma
1 trial -
D7632C00001
AstraZeneca AB
Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
1 trial -
D781PC00001
AstraZeneca AB
Advanced HER2-expressing Biliary Tract Cancer
1 trial -
D7984C00002
AstraZeneca AB
Locally advanced cervical cancer
1 trial -
D798AC00001
AstraZeneca AB
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
1 trial -
D8220C00027
AstraZeneca AB
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
D8227C00001
Lacuna Pharma Pty Ltd
Diffuse large B-cell lymphoma
1 trial -
D8532C00001
AstraZeneca AB
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1 trial -
D8534C00001
AstraZeneca AB
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
1 trial -
D8535C00001
AstraZeneca AB
ER+/HER2- Early Breast Cancer
1 trial -
D8991C00001
AstraZeneca AB
Advanced Platinum-resistant Epithelial Ovarian Cancer
1 trial -
D9078C00001
AstraZeneca AB
Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)
1 trial -
D9103C00001
AstraZeneca AB
Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation
1 trial -
D9106C00001
AstraZeneca AB
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).
1 trial -
D910DC00001
AstraZeneca AB
Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)
1 trial -
D910GC00001
AstraZeneca AB
Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
1 trial -
D910PC00001 - Volga
AstraZeneca AB
Bladder Cancer
1 trial -
D910SC00001/KUNLUN
AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
1 trial -
D910VC00001
AstraZeneca AB
Locoregional Hepatocellular Carcinoma (HCC)
1 trial -
D9268C00001
AstraZeneca AB
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"
1 trial -
D926PC00001
AstraZeneca AB
Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
1 trial -
D926QC00001
AstraZeneca AB
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
1 trial -
D926TC00001
AstraZeneca AB
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature
1 trial -
D9311C00001
AstraZeneca AB
Endometrial Cancer
1 trial -
D933AC00001
AstraZeneca AB
First-line patients with advanced biliary tract cancers (BTC)
1 trial -
D933QC00001
AstraZeneca AB
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
1 trial -
D933SC00001
AstraZeneca AB
Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
1 trial -
D9670C00001
AstraZeneca AB
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
1 trial -
D967RC00001
AstraZeneca AB
Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)
1 trial -
D967SC00001
AstraZeneca AB
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
1 trial -
D967UC00001
AstraZeneca AB
HER2-positive metastatic breast cancer
1 trial -
D9722C00001
AstraZeneca AB
Advanced Breast Cancer
1 trial -
D9723C00001
AstraZeneca AB
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
1 trial -
D9727C00001
AstraZeneca AB
Prostate Cancer
1 trial -
D9802C00001
AstraZeneca AB
Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
1 trial -
DAC-HAAG-02
Hospital Authority, Hong Kong
Acute Myeloid Leukemia
1 trial -
DANTE/FLOT8
The George Institute
locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach
1 trial -
DANUBE/D419BC00001
AstraZeneca AB
Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.
1 trial -
DARAXONRASIB (RMC-6236), DARAXONRASIB (RMC-6236)
Revolution Medicines
Resected Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
DAUNORUBICIN for Favorable-intermediate-risk Acu…
Fondazione Telethon ETS
Favorable-intermediate-risk Acute Myeloid Leukemia
1 trial -
DCC-2618-03-002
Lacuna Pharma Pty Ltd
Patients with Advanced Gastrointestinal Stromal Tumors
1 trial -
DCC-3014-03-001
Lacuna Pharma Pty Ltd
Tenosynovial Giant Cell Tumor
1 trial
Frequently asked questions
How many oncology Phase III programs exist?
1,266 programs match both the therapeutic area and stage filters in our published index.